Stockscreener 앱 받기
6.54
0.00%
0.00
전일 마감가:
$6.54
열려 있는:
$6.47
하루 거래량:
13,712
Relative Volume:
0.15
시가총액:
$43.78M
수익:
$28.83M
순이익/손실:
$-13.34M
주가수익비율:
-4.3026
EPS:
-1.52
순현금흐름:
$-7.49M
1주 성능:
-10.16%
1개월 성능:
-21.39%
6개월 성능:
-35.05%
1년 성능:
+323.30%
1일 변동 폭
$6.47
$6.93
1주일 범위
$6.17
$7.50
52주 변동 폭
$1.44
$36.00
Exicure Inc Stock (XCUR) Company Profile
명칭
Exicure Inc
전화
847-673-1707
주소
2430 N. HALSTED ST., CHICAGO, IL
XCUR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.4126 | 597.27M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.39 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.04 | 128.33M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1589 | 360.17M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.20 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-20 | 개시 | Guggenheim | Buy |
Exicure Inc 주식(XCUR)의 최신 뉴스
What makes Exicure Inc. stock price move sharplyStrategic High Profit Opportunities - Newser
Why Exicure Inc. stock attracts strong analyst attentionMarket Beating Strategy - Newser
Exicure Media Files Secondary Offering for Investors - MarketScreener
Exicure files for prospectus offering 5.2 mln common stock offered by selling stockholders - MarketScreener
How Exicure Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - beatles.ru
Exicure (NASDAQ:XCUR) Stock Price Up 2.3% – Should You Buy? - Defense World
When the Price of (XCUR) Talks, People Listen - news.stocktradersdaily.com
Exicure Plunges 11.36% Despite Russell Microcap Index Inclusion - AInvest
Exicure, Inc.(NasdaqCM: XCUR) added to Russell 3000E Index - MarketScreener
Exicure, Inc. Reports First Quarter 2025 Financial Results - BioSpace
Is Exicure, Inc. overvalued or undervalued? - MarketsMojo
Exicure (NASDAQ:XCUR) Stock Price Down 5.8% – Here’s Why - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement — Here’s How to Get Your Share - TradingView
What's Going On With Exicure Shares Monday? - MSN
Trading (XCUR) With Integrated Risk Controls - news.stocktradersdaily.com
XCURExicure, Inc. Reports Full Year 2024 Financial Results - mx.advfn.com
Exicure faces Nasdaq non-compliance notice By Investing.com - Investing.com South Africa
(XCUR) Trading Report - news.stocktradersdaily.com
Exicure Receives Nasdaq Delinquency Notification - TipRanks
Exicure faces Nasdaq non-compliance notice - Investing.com Australia
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q | XCUR Stock News - GuruFocus
Exicure Receives Noncompliance Notice From Nasdaq - marketscreener.com
Exicure (XCUR) Faces Nasdaq Non-Compliance Due to Delayed Report | XCUR Stock News - GuruFocus
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Business Wire
Exicure (NASDAQ:XCUR) Trading Down 4.5% – Here’s Why - Defense World
Exicure (XCUR) Is Paying a $5.6M Settlement to Investors — Here’s How to Get Your Share - TradingView
Exicure Delays 10-Q Filing Amid Acquisition - TipRanks
(XCUR) Investment Analysis and Advice - news.stocktradersdaily.com
Exicure enters strategic convertible bond agreement By Investing.com - Investing.com Nigeria
Exicure Enters Convertible Bond Agreement with Subsidiary - TipRanks
Exicure enters strategic convertible bond agreement - Investing.com
Exicure concludes subject enrolment in trial of GPC-100 for multiple myeloma - Yahoo Finance
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant | XCUR Stock News - GuruFocus
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
Geode Capital Management LLC Purchases Shares of 12,645 Exicure, Inc. (NASDAQ:XCUR) - Defense World
Exicure, Inc. (NASDAQ:XCUR) Sees Significant Drop in Short Interest - Defense World
Investors Can Still File Late Claims for Exicure $5.6M Settlement Payouts - TradingView
Why Exicure Inc. (XCUR) Soared on Monday - MSN
How To Trade (XCUR) - news.stocktradersdaily.com
10 Micro-, Small-Cap Companies Lead Monday’s Charge - Insider Monkey
Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest - Defense World
Exicure Close to Finishing Patient Recruitment in Phase 2 Study of GPC-100 in Multiple Myeloma - MarketScreener
Exicure appoints new independent accounting firm By Investing.com - Investing.com India
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma - BioSpace
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study o - GuruFocus
Exicure appoints new independent accounting firm - Investing.com Australia
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) - BioSpace
Exicure Inc (XCUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
2.49%
자본화:
|
볼륨(24시간):